Liminatus Pharma, Inc. (LIMNW)
NCM
$0.04
-20.83%
Closing price as of 2026-09-09 · Source: TEK2day Finance
Key Metrics
Exchange
NCM
Currency
USD
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (701K) | (884K) | (1.1M) | (1.4M) |
| Net Income | (1.8M) | (8.2M) | (1.1M) | (1.4M) |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (2.7M) | (4.8M) | (3.3M) | (3.0M) |
| Net Income | (2.9M) | (5.0M) | (3.5M) | (10.2M) |